BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report report published on Tuesday.

Several other equities research analysts also recently commented on the company. ValuEngine raised Antares Pharma from a hold rating to a buy rating in a report on Wednesday, August 8th. HC Wainwright set a $4.00 target price on Antares Pharma and gave the company a buy rating in a report on Wednesday, August 8th.

Shares of NASDAQ ATRS opened at $3.45 on Tuesday. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $4.09. The firm has a market cap of $455.78 million, a PE ratio of -31.36 and a beta of 0.19. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.33 and a quick ratio of 1.89.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Antares Pharma had a negative net margin of 35.53% and a negative return on equity of 64.96%. The company had revenue of $14.16 million for the quarter, compared to analysts’ expectations of $13.70 million. research analysts anticipate that Antares Pharma will post -0.1 earnings per share for the current fiscal year.

In other news, Director Jacques Gonella sold 200,000 shares of the company’s stock in a transaction on Wednesday, May 23rd. The stock was sold at an average price of $2.52, for a total transaction of $504,000.00. Following the completion of the sale, the director now directly owns 11,160,033 shares of the company’s stock, valued at $28,123,283.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 1,236,115 shares of company stock valued at $3,365,861. 12.20% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of ATRS. Mycio Wealth Partners LLC acquired a new position in Antares Pharma during the second quarter valued at $6,278,000. FMR LLC raised its position in Antares Pharma by 38.8% during the second quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock valued at $9,393,000 after buying an additional 1,018,300 shares during the period. Russell Investments Group Ltd. acquired a new position in Antares Pharma during the first quarter valued at $1,959,000. BlackRock Inc. raised its position in Antares Pharma by 7.3% during the second quarter. BlackRock Inc. now owns 9,805,325 shares of the specialty pharmaceutical company’s stock valued at $25,298,000 after buying an additional 664,681 shares during the period. Finally, United Services Automobile Association raised its position in Antares Pharma by 1,453.0% during the second quarter. United Services Automobile Association now owns 405,261 shares of the specialty pharmaceutical company’s stock valued at $21,147,000 after buying an additional 379,166 shares during the period. 38.31% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Stock Symbol

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.